Skip Navigation LinksHome > March 2014 - Volume 114 - Issue 3 > New Drug for Hepatitis C Infection
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000444528.06303.4c
Drug Watch

New Drug for Hepatitis C Infection

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* Simeprevir (Olysio) is a new protease inhibitor approved for the treatment of adults with hepatitis C viral infection. Simeprevir should be used as part of a combination therapy treatment plan.

* Genotype 1a hepatitis C virus with the NS3 Q80K polymorphism will not respond well to simeprevir therapy.

* Common adverse effects are rash (including photosensitivity), pruritis, and nausea.

© 2014 Lippincott Williams & Wilkins. All rights reserved.

Login